Tumor Hypoxia and Radioresistance

Authors

  • Sara Morović Opća bolnica Zadar, Zadar, Hrvatska Author

DOI:

https://doi.org/10.55378/rv.48.2.6

Keywords:

Tumor hypoxia, radioresistance, hypoxia-inducible factors (HIFs), radiotherapy, oxygen enhancement ratio (OER)

Abstract

Tumor hypoxia is a prevalent feature of solid tumors, significantly contributing to increased tumor aggressiveness, metastatic potential, and resistance to conventional therapies such as radiotherapy. This review explores the complex relationship between tumor hypoxia and radioresistance, highlighting the molecular mechanisms involved and potential therapeutic strategies to enhance radiotherapy efficacy in hypoxic tumors. Key mechanisms include the role of hypoxia-inducible factors (HIFs), particularly HIF-1α, which regulates numerous genes involved in tumor survival, proliferation, and resistance under hypoxic conditions. The review also discusses the oxygen enhancement ratio (OER) and its impact on radiotherapy outcomes, emphasizing how hypoxia leads to reduced radiosensitivity by limiting the formation of radiation-induced DNA damage. Despite the development of various strategies to counteract hypoxia-induced radioresistance, such as HIF inhibitors, hypoxia-targeted gene therapy, and hypoxia-activated prodrugs (HAPs), clinical results have been mixed, necessitating further research. Additionally, advances in imaging techniques for detecting tumor hypoxia are explored, which may allow for more personalized radiotherapy approaches, such as dose painting. The future of overcoming tumor hypoxia in radiotherapy lies in the integration of innovative therapeutic strategies, personalized medicine, and improved imaging technologies, offering hope for enhanced treatment outcomes in cancer patients.

References

Li Y, Zhao L, Li XF. Hypoxia and the tumor microenvironment. Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211036304. doi: 10.1177/15330338211036304

Bouleftour W, Rowinski E, Louati S, Sotton S, Wozny AS, Moreno-Acosta P, Mery B, Rodriguez-Lafrasse C, Magne N. A review of the role of hypoxia in radioresistance in cancer therapy. Med Sci Monit. 2021 Nov 3;27. doi: 10.12659/MSM.934116.

Zhuang Y, Liu K, He Q, Gu X, Jiang C, Wu J. Hypoxia signaling in cancer: Implications for therapeutic interventions. MedComm (2020). 2023 Jan 23;4(1). doi: 10.1002/mco2.203

Noman MZ, Hasmim M, Lequeux A, Xiao M, Duhem C, Chouaib S, Berchem G, Janji B. Improving cancer immunotherapy by targeting the hypoxic tumor microenvironment: New opportunities and challenges. Cells. 2019;8(9):1083. doi: 10.3390/cells8091083.

Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015 Dec 11;3:83-92. doi: 10.2147/HP.S93413.

Chen G, Wu K, Li H, Xia D, He T. Role of hypoxia in the tumor microenvironment and targeted therapy. Front Oncol. 2022 Sep 23;12:961637. doi: 10.3389/fonc.2022.961637.

Zhao Y, Xing C, Deng Y, Ye C, Peng H. HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies. Genes Dis. 2024;11(1):234-251. doi: 10.1016/j.gendis.2023.02.039.

Bouleftour W, Rowinski E, Louati S, Sotton S, Wozny AS, Moreno-Acosta P, Mery B, Rodriguez-Lafrasse C, Magne N. A review of the role of hypoxia in radioresistance in cancer therapy. Med Sci Monit. 2021 Nov 3;27 doi: 10.12659/MSM.934116.

Beckers C, Pruschy M, Vetrugno I. Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities. Semin Cancer Biol. 2024;98:19-30. doi: 10.1016/j.semcancer.2023.11.006. ISSN 1044-579X.

Scanlon SE, Glazer PM. Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment. DNA Repair (Amst). 2015 Aug;32:180-189. doi: 10.1016/j.dnarep.2015.04.030.

Infantino V, Santarsiero A, Convertini P, Todisco S, Iacobazzi V. Cancer cell metabolism in hypoxia: Role of HIF-1 as key regulator and therapeutic target. Int J Mol Sci. 2021;22(11):5703. doi: 10.3390/ijms22115703.

Greco O, Patterson AV, Dachs GU. Can gene therapy overcome the problem of hypoxia in radiotherapy? J Radiat Res. 2000;41:201-212.

Chen SY, Tsuneyama K, Yen MH, Lee JT, Chen JL, Huang SM. Hyperbaric oxygen suppressed tumor progression through the improvement of tumor hypoxia and induction of tumor apoptosis in A549-cell-transferred lung cancer. Sci Rep. 2021 Jun 8;11(1):12033. doi: 10.1038/s41598-021-91454-2.

Moen I, Stuhr LE. Hyperbaric oxygen therapy and cancer--a review. Target Oncol. 2012 Dec;7(4):233-42. doi: 10.1007/s11523-012-0233-x.

Telarovic I, Wenger RH, Pruschy M. Interfering with tumor hypoxia for radiotherapy optimization. J Exp Clin Cancer Res. 2021 Jun 21;40(1):197. doi: 10.1186/s13046-021-02000-x.

Gao HQ, Wan YZ, Bu XM, Fan XY, Xie XX, Ji XN, Song W. How to deal with the relationship between hypoxia and radiotherapy in the hypofractionated radiotherapy era? Int J Radiat Res. October 2021;19(4):759-769. doi: 10.29242/ijrr.19.4.759.

Moon EJ, Petersson K, Olcina MM. The importance of hypoxia in radiotherapy for the immune response, metastatic potential and FLASH-RT. Int J Radiat Biol. 2022;98(3):439-451. doi: 10.1080/09553002.2021.1988178.

Le QT, Courter D. Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev. 2008 Sep;27(3):351-62. doi: 10.1007/s10555-008-9144-9.

Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L, Kolb HC. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal. 2014 Oct 1;21(10):1516-54. doi: 10.1089/ars.2013.5378.

Le QT, Courter D. Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev. 2008 Sep;27(3):351-62. doi: 10.1007/s10555-008-9144-9.

Chiari G, Fiandaca G, Delitala ME. Hypoxia-related radiotherapy resistance in tumors: treatment efficacy investigation in an eco-evolutionary perspective. Front Appl Math Stat. 2023 Jul 13;9. doi: 10.3389/fams.2023.1193191.

Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomedicine. 2018 Oct 4;13:6049-6058. doi: 10.2147/IJN.S140462.

Musleh Ud Din S, Streit SG, Huynh BT, Hana C, Abraham A-N, Hussein A. Therapeutic targeting of hypoxia-inducible factors in cancer. Int J Mol Sci. 2024;25(4):2060. doi: 10.3390/ijms25042060.

Chen Z, Han F, Du Y, et al. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Sig Transduct Target Ther. 2023;8:70. doi: 10.1038/s41392-023-01332-8.

Beckers C, Pruschy M, Vetrugno I. Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities. Semin Cancer Biol. 2024;98:19-30. doi: 10.1016/j.semcancer.2023.11.006. ISSN 1044-579X.

COVER Tumor Hypoxia and Radioresistance

Downloads

Published

2024-10-07

Issue

Section

Professional papers

Categories

How to Cite

Morović, Sara. 2024. “Tumor Hypoxia and Radioresistance”. Radiological Journal 48 (2): 52-58. https://doi.org/10.55378/rv.48.2.6.

Similar Articles

1-10 of 25

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)